Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

First Large Study Comparing Leading Hepatitis C Therapies Provides

Important Insights to Help Guide Clinical Practice

MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Final results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C, were presented today at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), providing important insights that may help guide clinical practice for physicians worldwide treating this serious and potentially life-threatening disease.

The IDEAL study compared combination therapy with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP),(1) as well as a lower dose of PEGINTRON in an investigational combination with REBETOL. The results showed that sustained virologic response (SVR),(2) the primary endpoint of the study, was similar for all three treatment regimens. The study also showed in secondary analyses that PEGINTRON combination therapy provided greater predictability of response at important treatment milestones and significantly lower relapse rates after the end of treatment than Pegasys and Copegus combination therapy, despite patients in the Pegasys arm overall receiving a significantly higher median ribavirin dose over the duration of the study. Safety and tolerability were similar among the treatment arms.

"IDEAL provides important insights about the similarities and differences of the two leading combination therapies for hepatitis C, and how physicians can use these findings to help manage their patients," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute.

In IDEAL (Individualized Dosing Efficacy vs. flat dosing to assess optimaL pegylated interferon therapy), 3,070 previously untreated U.S. patients with HCV genotype 1, the most co
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mindray Medical International Limited (NYSE: MR ... medical devices worldwide, announced today that it has ... Report on Form 20-F that included audited financial ... electronic version of Mindray,s Annual Report on Form ... at  http://ir.mindray.com  or  http://www.sec.gov . Investors ...
(Date:4/16/2015)... MOUNTAIN VIEW, Calif. , April 16, 2015  Alexza ... its fiscal quarter ended March 31, 2015 on Wednesday, May ... The Company will also host an investor conference call and ... Time to provide a company update and discuss the financial ... Internet, go to www.alexza.com , under the "Investors" link.  ...
(Date:4/16/2015)... , April 16, 2015 Today, Kenneth C. ... & Co., Inc., was elected chairman of the Board of ... Board meeting, PhRMA,s president and CEO John J. Castellani ... 2016.  New Officers Elected to PhRMA Board ... succeeds Ian C. Read , chairman and CEO of ...
Breaking Medicine Technology:Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5
... 2012   Psyche Systems Corporation and Aperio ... offer the most advanced anatomic pathology information system ... pathologists can immediately access, manage, and evaluate their ... LIS via intuitive step-by-step workflows. ...
... treatment of the fermented soy germ-based nutritional supplement containing ... cholesterol and improved vascular stiffness, all factors that occur ... peer-reviewed study reported in a poster at the Women,s ... the first to provide evidence that a daily supplement ...
Cached Medicine Technology:Psyche Systems Corporation and Aperio® Announce Availability of Their Fully Integrated Anatomic Pathology System 2Soy-Based S-equol Supplement Reduces Metabolic Syndrome Risk Factors 2Soy-Based S-equol Supplement Reduces Metabolic Syndrome Risk Factors 3Soy-Based S-equol Supplement Reduces Metabolic Syndrome Risk Factors 4Soy-Based S-equol Supplement Reduces Metabolic Syndrome Risk Factors 5
(Date:4/17/2015)... California (PRWEB) April 17, 2015 At ... Entertainment’s EcoLuxe Lounge and the “Salute to the Oscars” ... luxurious Beverly Hilton Hotel, overlooking the impressive Los Angeles ... were organized by Debbie Durkin, LA’s leading producer of ... Showcasing many of the world’s premier providers of eco-friendly ...
(Date:4/17/2015)... 2015 Baptist Health and The University ... partnership agreement designed to transform oncology care in northeast ... agreed to create a joint cancer program to enhance ... research. Baptist MD Anderson Cancer Center is anticipated to ... destination for highly coordinated, multidisciplinary cancer care for adults ...
(Date:4/17/2015)... 17, 2015 The American College of Traditional Chinese ... Application Day on April 29. The event will be held from ... at 555 DeHaro St. in San Francisco, CA. , The agenda ... in at the DeHaro campus (room F), 11:10 a.m. – ... Noon – Light lunch with current students, faculty and staff, 1 ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog post explaining ... quotes . , The online environment can help ... Drivers should always compare multiple car insurance policies before ... a competitive one, which means that customers can find ... is now possible to compare online car insurance quotes ...
(Date:4/17/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining the ... car insurance rates . , Falling asleep at ... have a big impact on auto insurance prices. The premiums ... claimed benefits. The newly released blog post talks more about ... , It is now possible to find low cost ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:American College of Traditional Chinese Medicine Hosts Open House 2Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2
... 30 (HealthDay News) -- Genes affect hereditary coronary heart disease ... study. While it,s long been known that hereditary factors ... due to genes or unhealthy lifestyle in the family, the ... the investigators examined the health records of 80,214 adopted men ...
... It,s not how old but how frail patients are that can ... fact, young patients in poor health may have worse outcomes than ... the University of Michigan Comprehensive Cancer Center finds that patients with ... spread to distant parts of the body. These findings ...
... found that climate change may lead to more asthma-related health ... the next decade. The data, published in the current ... changing levels of ozone could lead to a 7.3 percent ... The research team, led by Perry Sheffield, ...
... 2011Despite recent concerns that changes in atmospheric pressure during ... via pump devices, the current evidence is limited and ... are available, according to an insightful editorial in ... by Mary Ann Liebert, Inc. The editorial is available ...
... by extroverted college students and their less socially inclined peers ... on partying and drinking to be happy and more on ... positive thinking. "You don,t have to go out ... they need to do, particularly when they,re new to campus," ...
... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay News) -- Swedish ... seems to be a harbinger of an increased risk of ... strongly tied to the inflammatory processes that are central to ... of the new study, published online Aug. 30 in the ...
Cached Medicine News:Health News:Patients' underlying health linked to worse outcomes for melanoma, U-M study finds 2Health News: Happiness: All in who you know, goals 2Health News:Blood Protein Might Signal Death Risk in Elderly 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: